logo
Plus   Neg
Share
Email

Coca-Cola Maintains FY20 Outlook; Provides COVID-19 Impact On Q1 - Quick Facts

Coca-Cola Co. (KO) on Friday reaffirmed its guidance for the full-year 2020 and provided an update on the expected impact from COVID-19 on first quarter 2020 results, ahead of its presentation at the Consumer Analyst Group of New York (CAGNY) Conference.

For fiscal 2020, the company continues to project comparable earnings to be about $2.25 per share on organic revenue growth of about 5 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.26 per share on revenue growth of 4.7 percent to $39.05 billion for the year. Analysts' estimates typically exclude special items.

Meanwhile, the company said it currently estimates an approximate 2- to 3-point impact to unit case volume, 1- to 2-point impact to organic revenue and 1- to 2-penny impact to earnings per share for the first quarter due to COVID-19.

However, the situation with COVID-19 or coronavirus continues to evolve, and the company expects to provide more information during its next earnings call in April.

China ranks as the third-largest market in the world for The Coca-Cola Company in terms of unit case volume.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT